Literature DB >> 513486

Study of factors which modify the development of norepinephrine-induced acute renal failure in the dog.

R V Patak, S Z Fadem, M D Lifschitz, J H Stein.   

Abstract

Previous studies have demonstrated that the fall in inulin clearance which occurs 3 hours after the intrarenal administration of norepinephrine can be markedly attenuated by the prior administration of intrarenal prostaglandin E2 (PGE). Since in the previous studies PGE led to a marked increase in both renal blood flow and solute excretion, we designed the present series of experiments to investigate whether an increase in renal blood flow, solute excretion, or other factors were responsible for the protective effect in the norepinephrine model. Two renal vasodilators, bradykinin and secretin, were evaluated initially. Bradykinin administration prior to norepinephrine administration had a protective effect similar to that previously found with PGE, whereas secretin did not. Both of these vasocilators increased renal blood flow to the same degree, but only bradykinin increased urine flow and solute excretion. The fall in inulin clearance 3 hours after the administration of norepinephrine was also attenuated by two diuretics (mannitol and furosemide) which tended to increase renal blood flow. In contrast, two natriuretic agents, which are also renal vasoconstrictors (chlorothiazide and benzolamide), had no protective effect. Further, chlorothiazide and benzolamide obviated the protective effect of bradykinin. These studies demonstrate that there are several types of pharmacologic agents which can modify the magnitude of renal functional impairment resulting from extreme renal ischemia. Although the mechanism of the protective effects remain unclear, the findings are compatible with the view that the protective effect noted with PGE, bradykinin, mannitol, and furosemide may be related to an increase in osmolar excretion which occurred with administration of each of these agents. This potentially salutory effect (increased osmolar excretion), however, could be overcome by an agent (e.g., chlorothiazide or benzolamide) which also increased renal resistance prior to the administration of norepinephrine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 513486     DOI: 10.1038/ki.1979.30

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

Review 1.  Acute renal failure in the intensive care unit. Part 2.

Authors:  H L Corwin; J V Bonventre
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

2.  Hypoxia-inducible transcription factors stabilization in the thick ascending limb protects against ischemic acute kidney injury.

Authors:  Gunnar Schley; Bernd Klanke; Johannes Schödel; Frauke Forstreuter; Deepa Shukla; Armin Kurtz; Kerstin Amann; Michael S Wiesener; Seymour Rosen; Kai-Uwe Eckardt; Patrick H Maxwell; Carsten Willam
Journal:  J Am Soc Nephrol       Date:  2011-09-15       Impact factor: 10.121

Review 3.  Cellular mechanism of ischemic acute renal failure: role of Ca2+ and calcium entry blockers.

Authors:  R W Schrier; J Hensen
Journal:  Klin Wochenschr       Date:  1988-09-15

Review 4.  Calcium handling by renal tubules during oxygen deprivation injury to the kidney prior to reoxygenation.

Authors:  T J Burke; H Singh; R W Schrier
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

5.  Nature of the renal injury following total renal ischemia in man.

Authors:  B D Myers; D C Miller; J T Mehigan; C O Olcott; H Golbetz; C R Robertson; G Derby; R Spencer; S Friedman
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

6.  Oxygen free radicals in ischemic acute renal failure in the rat.

Authors:  M S Paller; J R Hoidal; T F Ferris
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

7.  Protective effect of intrarenal calcium membrane blockers before or after renal ischemia. Functional, morphological, and mitochondrial studies.

Authors:  T J Burke; P E Arnold; J A Gordon; R E Bulger; D C Dobyan; R W Schrier
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

8.  The early phase of experimental acute renal failure. VI. The influence of furosemide.

Authors:  J Mason; H Kain; J Welsch; J Schnermann
Journal:  Pflugers Arch       Date:  1981-12       Impact factor: 3.657

9.  In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure.

Authors:  M Nakamoto; J I Shapiro; P F Shanley; L Chan; R W Schrier
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.